Anti-Human CD340/ERBB2 & CD279/PD-1 Bispecific Reference Antibody (Fidasimtamab, RUO)

Description: Fidasimtamab (BS10759) is a research-grade recombinant antibody targeting CD340. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.4mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: p185erbB2,HER2,NGL,Tyrosinekinase-typecellsurfacereceptorHER2,NEU,MLN19,Proto-oncogeneNeu,MLN19,ERBB2,Proto-oncogenec-ErbB-2,CD340,Receptortyrosine-proteinkinaseerbB-2,Metastaticlymphnodegene19protein,Programmedcelldeathprotein1,ProteinPD-1,hPD-1,PD1,PDCD1,CD279
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific,BH-2950,BH2950,IBI315,IBI-315,IBI315CAS:2377419-89-9
Background: Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity.
Note: For research use only. Not suitable for clinical or therapeutic use.